Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 229,809 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57. Following the completion of the sale, the director owned 686,477 shares of the company’s stock, valued at $62,970,535.21. The trade was a 25.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12.
• On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.23, for a total transaction of $556,594.23.

Kymera Therapeutics Stock Up 2.1%

NASDAQ:KYMR opened at $89.68 on Friday. The firm has a market capitalization of $6.45 billion, a P/E ratio of -24.98 and a beta of 2.28. The company has a fifty day moving average of $64.77 and a 200 day moving average of $51.85. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Larson Financial Group LLC increased its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its stake in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after acquiring an additional 815 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada started coverage on Kymera Therapeutics in a research note on Tuesday, September 16th. They set an “outperform” rating and a $70.00 target price on the stock. Truist Financial upped their target price on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Leerink Partners boosted their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $112.80.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.